Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat with Gem/Bu/Mel Conditioning for ASCT in R/R Myeloma
NCT02506959Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat in multiple myeloma (MM), plasma cell leukemia (PCL) and plasmacytoma (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 1 year. Started Sep 2015; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)plasmacytoma
Beyond the preview
Go deeper on NCT02506959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506959.